Pharmacokinetic phase (DDI phase) |
|
Completed |
26 (81.3) |
Entered post-DDI (treatment) phase |
26 (81.3) |
Discontinued from PK phase
|
6 (18.8)
|
Entered post-DDI (treatment) phase |
1 (3.1) |
Entered post-treatment follow-up phase |
1 (3.1) |
Primary reason for discontinuation from PK phase
|
|
Adverse event |
2 (6.3) |
Physician decision |
2 (6.3) |
Progressive disease |
1 (3.1) |
Death |
1 (3.1) |
Post-DDI (treatment) phase |
|
Discontinued from post-DDI (treatment) phase |
27 (84.4) |
Primary reason for discontinuation from treatment phase |
|
Progressive disease |
20 (62.5) |
Physician decision |
3 (9.4) |
Death |
2 (6.3) |
Adverse event |
1 (3.1) |
Lost to follow-up |
1 (3.1) |
Post-treatment follow-up |
|
Discontinued from post-treatment follow-up |
1 (3.1) |
Primary reason for discontinuation from post-treatment follow-up |
|
Protocol deviation |
1 (3.1) |